4,586 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Purchased by Aquatic Capital Management LLC

Aquatic Capital Management LLC purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 4,586 shares of the company’s stock, valued at approximately $64,000.

Several other institutional investors also recently bought and sold shares of TYRA. Boothbay Fund Management LLC purchased a new position in shares of Tyra Biosciences in the fourth quarter valued at approximately $244,000. Susquehanna Fundamental Investments LLC purchased a new position in Tyra Biosciences in the 4th quarter valued at $543,000. Dimensional Fund Advisors LP boosted its stake in Tyra Biosciences by 283.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 37,981 shares of the company’s stock worth $528,000 after purchasing an additional 28,074 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Tyra Biosciences by 175.7% during the fourth quarter. Marshall Wace LLP now owns 54,077 shares of the company’s stock worth $752,000 after buying an additional 34,463 shares in the last quarter. Finally, Jump Financial LLC acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $211,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TYRA has been the subject of several research reports. UBS Group initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Finally, Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Price Performance

Shares of NASDAQ TYRA opened at $10.50 on Tuesday. The company has a market capitalization of $557.45 million, a P/E ratio of -6.52 and a beta of 1.17. The company has a 50 day simple moving average of $9.77 and a 200-day simple moving average of $13.62. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. As a group, research analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Nina S. Kjellson sold 5,401 shares of Tyra Biosciences stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the sale, the director now directly owns 443,885 shares in the company, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 15.40% of the company’s stock.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.